BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210429T083000
DTEND;TZID=America/New_York:20210429T163000
DTSTAMP:20210426T035245Z
CREATED:20210401T184632Z
LAST-MODIFIED:20210426T035245Z
UID:13681-1619685000-1619713800@scienceinboston.com
SUMMARY:6th Annual RNA Medicine Symposium
DESCRIPTION:April 29\, 2021\, 8:30 am – 4:30 pm EST \n\nVirtual Presentation \nSponsored by the HMS Initiative for RNA Medicine and the Cancer Center at Beth Israel Deaconess Medical Center \nRegistration is Now Open! \nhttps://avfx.zoom.us/webinar/register/WN_3xTx9PR-T4KxHkU0y5NvzA
URL:https://scienceinboston.com/event/6th-annual-rna-medicine-symposium/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210429T083000
DTEND;TZID=America/New_York:20210429T163000
DTSTAMP:20210401T184632Z
CREATED:20210401T184632Z
LAST-MODIFIED:20210401T184632Z
UID:27690-1619685000-1619713800@scienceinboston.com
SUMMARY:6th Annual RNA Medicine Symposium
DESCRIPTION:April 29\, 2021\, 8:30 am – 4:30 pm EST \n\nVirtual Presentation \nSponsored by the HMS Initiative for RNA Medicine and the Cancer Center at Beth Israel Deaconess Medical Center \nRegistration is Now Open! \nhttps://avfx.zoom.us/webinar/register/WN_3xTx9PR-T4KxHkU0y5NvzA
URL:https://scienceinboston.com/event/6th-annual-rna-medicine-symposium-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210429T090000
DTEND;TZID=America/Vancouver:20210429T100000
DTSTAMP:20210419T033106Z
CREATED:20210419T033106Z
LAST-MODIFIED:20210419T033106Z
UID:14004-1619686800-1619690400@scienceinboston.com
SUMMARY:Dana-Farber Targeted Protein Degradation: A Chemical Biology Approach to DUBs​
DESCRIPTION:A Chemical Biology Approach to DUBs​​\n\nWebinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ \nHost: Vidyasagar Koduri \n​Sara Buhrlage\, PhD\, is an Assistant Professor in Dana-Farber’s Cancer Biology Department and Harvard Medical School’s Biological Chemistry and Molecular Pharmacology Department. Her research group focuses on the development of first-in-class inhibitors and prototype drugs for deubiquitylating enzymes (DUBs) that can be utilized to pharmacologically validate members of the gene family as new targets for cancer treatment and other diseases. DUBs have garnered significant attention recently as potential therapeutic targets in the field of oncology due to their removal of degradative ubiquitin marks from cancer causing proteins. \nPrior to joining as a faculty member in July 2015\, Dr. Buhrlage was a professional track scientist at Dana-Farber in the medicinal chemistry core laboratory. In this role she collaborated with Institute researchers to pharmacologically validate novel targets of disease and study mechanisms of oncogenesis and drug resistance. \nDr. Buhrlage completed a Doctor of Philosophy in organic chemistry in 2008\, under the direction of Professor Anna Mapp\, PhD\, from the University of Michigan\, where she successfully designed\, synthesized and characterized small molecules that bind the transcriptional co-activator CBP and upregulate transcription when tethered to DNA. Following completion of her Doctor of Philosophy\, Dr. Buhrlage trained for two years in medicinal chemistry at the Broad Institute.
URL:https://scienceinboston.com/event/dana-farber-targeted-protein-degradation-a-chemical-biology-approach-to-dubs%e2%80%8b/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210429T090000
DTEND;TZID=America/Vancouver:20210429T100000
DTSTAMP:20210419T033106Z
CREATED:20210419T033106Z
LAST-MODIFIED:20210419T033106Z
UID:27695-1619686800-1619690400@scienceinboston.com
SUMMARY:Dana-Farber Targeted Protein Degradation: A Chemical Biology Approach to DUBs​
DESCRIPTION:A Chemical Biology Approach to DUBs​​\n\nWebinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ \nHost: Vidyasagar Koduri \n​Sara Buhrlage\, PhD\, is an Assistant Professor in Dana-Farber’s Cancer Biology Department and Harvard Medical School’s Biological Chemistry and Molecular Pharmacology Department. Her research group focuses on the development of first-in-class inhibitors and prototype drugs for deubiquitylating enzymes (DUBs) that can be utilized to pharmacologically validate members of the gene family as new targets for cancer treatment and other diseases. DUBs have garnered significant attention recently as potential therapeutic targets in the field of oncology due to their removal of degradative ubiquitin marks from cancer causing proteins. \nPrior to joining as a faculty member in July 2015\, Dr. Buhrlage was a professional track scientist at Dana-Farber in the medicinal chemistry core laboratory. In this role she collaborated with Institute researchers to pharmacologically validate novel targets of disease and study mechanisms of oncogenesis and drug resistance. \nDr. Buhrlage completed a Doctor of Philosophy in organic chemistry in 2008\, under the direction of Professor Anna Mapp\, PhD\, from the University of Michigan\, where she successfully designed\, synthesized and characterized small molecules that bind the transcriptional co-activator CBP and upregulate transcription when tethered to DNA. Following completion of her Doctor of Philosophy\, Dr. Buhrlage trained for two years in medicinal chemistry at the Broad Institute.
URL:https://scienceinboston.com/event/dana-farber-targeted-protein-degradation-a-chemical-biology-approach-to-dubs/
LOCATION:Online
END:VEVENT
END:VCALENDAR